Bridger Management, LLC Immuno Gen, Inc. Transaction History

Bridger Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $1.75 Million - $9.37 Million	467,220 New	467,220 $8.82 Million
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $705,600 - $1.29 Million	-224,000 Reduced 44.62%	278,000 $1.25 Million
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $2.14 Million - $3.75 Million	502,000 New	502,000 $2.39 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Bridger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridger Management, LLC with notifications on news.